ORAMED PHARMACEUTICALS INC.

ORMP

ORAMED PHARMACEUTICALS INC.

ORMP

Insider Sentiment (TTM):

Last Purchase:2023-04-04Last Sale:2023-03-14Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:13,160,970Shares Outstanding:40,773,866Institutional Ownership Pct.:32.28%

Earnings Market Reaction:

Filing Date:2026-08-10Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Cash And Cash Equivalents At Carrying Value	15	13	46	52	16	75	54	42	85	19	9	5
Deposits Assets Current	-	11	11	4	23	27	55	43	2	80	95	120
Short Term Investments	-	-	-	-	-	-	-	57	66	78	58	-
Marketable Securities Current	1	5	5	5	2	4	3	-	-	-	-	-
Assets Current
Assets Current	53	68	133	136	99	131	143	143	153	177	163	176
Equity Securities Fv Ni	35	37	64	74	58	26	29	-	-	-	58	-
Prepaid Expense And Other Assets Current	2	2	3	1	1	1	1	0	1	1	1	1
Deposits Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Marketable Securities Noncurrent	22	18	8	-	-	4	-	1	2	2	2	3
Investment Owned At Fair Value	87	51	10	11	9	5	7	-	-	20	51	-
Assets Noncurrent
Assets Noncurrent	316	201	98	84	63	16	12	22	31	27	58	55
Equity Method Investments	-	-	-	-	-	1	-	-	-	-	-	-
Investments In Affiliates Subsidiaries Associates …	199	102	72	65	44	-	-	-	-	-	-	-
Equity Method Investments Fair Value Disclosure	0	0	1	1	3	-	-	-	-	-	-	-
Real Estate Investments	-	-	2	2	2	-	-	-	-	-	-	-
Other Long Term Investments	2	2	-	-	-	-	-	-	-	-	-	-
Equity Securities F V N I Noncurrent	4	4	4	4	4	4	4	-	-	-	-	-
Other Assets Noncurrent	0	0	0	0	0	0	0	-	-	-	0	-
Property Plant And Equipment Net	1	1	1	1	1	1	1	1	1	1	1	1
Operating Lease Right Of Use Asset	1	1	1	1	1	0	0	0	1	1	1	1
Assets	370	269	231	220	162	148	155	165	184	204	221	231
Liabilities And Stockhold…
Accounts Payable And Accrued Liabilities Current	9	9	6	5	2	5	5	5	3	1	2	3
Long Term Investments
Liabilities Current
Liabilities Current	11	11	19	6	4	5	6	5	4	34	53	78
Short Term Borrowings	-	-	-	-	-	-	-	-	-	32	51	75
Notes Payable Current	-	-	1	0	0	0	0	0	-	0	0	-
Deferred Income Current	-	-	1	1	1	-	-	-	-	-	-	-
Contract With Customer Liability Current	2	1	-	-	-	-	-	-	-	-	-	-
Dividends Payable Current	0	0	11	-	-	-	-	-	-	-	-	-
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Revenue Noncurrent	-	-	-	-	-	-	-	-	-	4	4	4
Liability For Uncertain Tax Positions Noncurrent	-	-	-	-	-	-	-	-	-	-	0	-
Taxes Payable Current And Noncurrent	-	-	-	-	-	-	-	0	0	0	0	-
Contract With Customer Liability Noncurrent	-	-	2	2	2	2	4	4	4	-	4	-
Employee Related Liabilities Current And Noncurren…	-	-	-	-	-	-	-	0	0	0	0	0
Liabilities Noncurrent
Deferred Income Noncurrent	-	-	1	1	2	-	-	-	-	-	-	-
Liabilities Noncurrent	41	20	12	12	4	2	4	4	4	4	4	4
Deferred Income	1	2	-	-	-	-	-	-	-	-	-	-
Operating Lease Liability Noncurrent	0	0	1	1	1	0	0	0	0	0	0	0
Other Liabilities	-	-	-	-	-	-	-	-	-	0	0	0
Other Liabilities Noncurrent	-	-	-	-	-	-	0	0	0	-	0	-
Dividends Payable Current And Noncurrent	0	0	0	-	-	-	-	-	-	-	-	-
Deferred Income Tax Liabilities Net	40	18	8	8	-	-	-	-	-	-	-	-
Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	324	323	323	325	325	325	322	322	323	322	321	320
Retained Earnings Accumulated Deficit	-7	-85	-123	-123	-171	-184	-177	-166	-147	-156	-158	-171
Stockholders Equity	317	238	200	202	154	141	146	156	177	167	164	149
Minority Interest	-	-	-	-1	-1	-1	-1	-1	-1	-1	-1	-1
Liabilities And Stockholders Equity	370	269	231	220	162	148	155	165	184	204	221	231
Common Stock Par Or Stated Value Per Share	0.012	0.012	0.012	0.012	0.012	0.012	0.012	0.012	0.012	0.012	0.012	0.012
Common Stock Shares Authorized	60	60	60	60	60	60	60	60	60	60	60	60
Common Stock Shares Issued	41	41	39	41	41	41	40	40	41	41	40	40
Shares Outstanding	41	41	39	41	41	41	40	40	41	41	40	40

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-10.62%	-6.70%	-0.69%	-	-	-	12.08%	21.25%	50.62%	16.87%	39.76%	16.57%
2025	0.91%	-0.91%	-3.64%	5.19%	15.09%	12.74%	-0.42%	-0.42%	-4.62%	-6.52%	-6.52%	-7.83%
2024	-8.40%	7.98%	9.24%	4.91%	4.91%	3.57%	9.23%	18.46%	18.97%	1.74%	-14.29%	-18.47%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	4.98	6.45	6.98	22.24	26.81	23.94	25.19	27.08	41.06	5.28	3.06	2.25
Quick Ratio	4.77	6.23	6.84	22.01	26.52	23.79	24.97	26.99	40.92	5.26	3.05	2.24
Working Capital	42.68M	57.59M	114.19M	130.00M	95.33M	125.98M	137.54M	137.50M	149.54M	143.54M	109.37M	97.53M
Leverage & Debt
Debt to Equity	0.16	0.13	0.16	0.09	0.05	0.05	0.07	0.06	0.05	0.23	0.35	0.56
Interest Coverage TTM	-	-	-	-	-14.98	-12.05	-6.97	-4.01	-3.99	-4.45	-6.03	-62.57
Debt Ratio	0.14	0.11	0.13	0.08	0.05	0.05	0.06	0.06	0.04	0.19	0.26	0.36
Efficiency & Turnover
Asset Turnover TTM	0.01	0.01	0.02	0.02	0.01	0.01	0.00	0.00	0.01	0.01	0.01	0.02
Per Share Metrics
Diluted EPS TTM	1.51	-0.02	-1.10	1.14	-0.45	-0.56	-0.34	-0.28	0.12	-0.13	-0.26	0.65
Free Cash Flow Per Share TTM	-0.22	-0.31	-0.32	-0.35	-0.20	-0.07	-0.02	-0.01	-0.26	-0.37	-0.48	-0.66
Dividend Per Share TTM	0.50	0.25	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-754.40%	-740.55%	-391.30%	-302.98%	-639.05%	-671.35%	-	-	-1,176.79%	-815.54%	-696.68%	-1,537.64%
Net Profit Margin TTM	3,200.80%	-42.60%	-1,170.10%	1,223.35%	-955.15%	-1,158.95%	-	-	379.70%	-269.96%	-386.87%	781.88%
Growth Metrics
Net Revenue Growth (1Y)	0.00%	0.00%	-	-	49.25%	-0.70%	-100.00%	-100.00%	-50.43%	-25.49%	-0.85%	24.67%
Net Income Growth (1Y)	-435.11%	-96.32%	234.29%	-531.82%	-475.45%	326.32%	35.04%	-143.12%	-86.08%	-111.23%	-116.66%	-26.82%
EPS Growth (1Y)	-440.85%	-96.28%	229.83%	-522.93%	-468.40%	322.26%	33.27%	-142.65%	-86.33%	-111.01%	-116.12%	-29.25%
Valuation Metrics
P/E TTM	3.08	-162.71	-2.35	2.10	-4.58	-3.55	-6.58	-8.21	19.29	-20.45	-8.37	3.74
P/B TTM	0.62	0.58	0.55	0.51	0.57	0.59	0.63	0.60	0.56	0.67	0.53	0.66
P/S TTM	98.70	69.32	27.50	25.69	43.78	41.13	-	-	73.23	55.19	32.39	29.28
Market Cap	197.40M	138.63M	110.00M	102.77M	87.56M	82.25M	92.16M	93.03M	98.13M	111.16M	86.82M	98.41M
Enterprise Value	182.16M	125.43M	64.71M	50.59M	71.80M	7.77M	38.07M	50.96M	13.38M	124.62M	129.10M	168.31M
Calculated Values
Free Cash Flow TTM	-9.15M	-12.49M	-13.09M	-14.55M	-8.43M	-2.82M	-775.00K	-270.00K	-10.55M	-15.28M	-19.53M	-26.50M
Net Debt	-15.25M	-13.20M	-45.30M	-52.18M	-15.76M	-74.48M	-54.09M	-42.07M	-84.75M	13.46M	42.28M	69.90M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2023-04-04Purchase

Owner: Mayer, Arie

Title: -

Shares: 3,800

Price/Share: $2.21

Value: $8,398.00

Shares Owned: 26,809

Relationship: Director

Ownership: Direct

2023-03-16Purchase

Owner: Kidron, Nadav

Title: President and CEO

Shares: 26,000

Price/Share: $2.04

Value: $53,040.00

Shares Owned: 126,000

Relationship: Director,Officer

Ownership: Indirect

2023-03-14Sale

Owner: Kidron, Miriam

Title: Chief Scientific Officer

Shares: 100,000

Price/Share: $2.01

Value: $201,000.00

Shares Owned: 201,666

Relationship: Director,Officer

Ownership: Direct

2023-03-14Purchase

Owner: Kidron, Nadav

Title: President and CEO

Shares: 100,000

Price/Share: $2.01

Value: $201,000.00

Shares Owned: 100,000

Relationship: Director,Officer

Ownership: Indirect

2023-03-14Purchase

Owner: Rozov, Yadin

Title: -

Shares: 50,000

Price/Share: $2.05

Value: $102,500.00

Shares Owned: 86,500

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2023-04-04	Mayer, Arie	Director	-	Direct	Purchase	3,800	2.21	$8,398.00	26,809	4
2023-03-16	Kidron, Nadav	Director,Officer	President and CEO	Indirect	Purchase	26,000	2.04	$53,040.00	126,000	4
2023-03-14	Kidron, Miriam	Director,Officer	Chief Scientific Officer	Direct	Sale	100,000	2.01	$201,000.00	201,666	4
2023-03-14	Kidron, Nadav	Director,Officer	President and CEO	Indirect	Purchase	100,000	2.01	$201,000.00	100,000	4
2023-03-14	Rozov, Yadin	Director	-	Direct	Purchase	50,000	2.05	$102,500.00	86,500	4
2023-01-03	Rabinowitz, Michael	Officer	Chief Commercial Officer	Direct	Sale	13,325	12.75	$169,893.75	126,143	4
2022-03-21	Rakin, Kevin	Director	-	Direct	Sale	10,000	9.41	$94,100.00	46,661	4
2021-11-01	Mayer, Arie	Director	-	Direct	Sale	3,000	25.60	$76,800.00	0	4
2021-09-16	Rakin, Kevin	Director	-	Direct	Sale	21,100	20.99	$442,889.00	57,004	4
2021-08-09	Kidron, Nadav	Director,Officer,TenPercentOwner	President and CEO	Direct	Sale	220,000	20.11	$4,424,200.00	738,209	4/A
2021-08-09	Kidron, Nadav	Director,Officer,TenPercentOwner	President and CEO	Direct	Sale	220,000	20.11	$4,424,200.00	648,573	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

32.28%

Inst. Shares: 13,160,970

Shares Outstanding: 40,773,866

2025-12-31

26.48%

Inst. Shares: 10,963,749

Shares Outstanding: 41,402,997

2025-09-30

17.30%

Inst. Shares: 7,223,413

Shares Outstanding: 41,756,301

2025-06-30

17.31%

Inst. Shares: 7,226,906

Shares Outstanding: 41,743,486

2025-03-31

18.71%

Inst. Shares: 7,715,082

Shares Outstanding: 41,228,782

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	13,160,970	40,773,866	32.28%
2025-12-31	10,963,749	41,402,997	26.48%
2025-09-30	7,223,413	41,756,301	17.30%
2025-06-30	7,226,906	41,743,486	17.31%
2025-03-31	7,715,082	41,228,782	18.71%
2024-12-31	7,643,533	40,850,446	18.71%
2024-09-30	6,921,690	40,896,845	16.92%
2024-06-30	5,068,416	40,959,759	12.37%
2024-03-31	5,073,708	40,835,953	12.42%
2023-12-31	4,765,020	40,315,068	11.82%
2023-09-30	2,096,588	40,445,896	5.18%
2023-06-30	2,008,213	40,225,594	4.99%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

ORAMED PHARMACEUTICALS INC. (ORMP) — SEC Financial Statements & Analysis

ORAMED PHARMACEUTICALS INC. (ORMP) is a pharmaceutical preparations company, incorporated in DE. ORAMED PHARMACEUTICALS INC. trades on Nasdaq as: ORMP. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), ORAMED PHARMACEUTICALS INC. reported a 0.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.16x, a Price-to-Sales (P/S) ratio of 98.70x (TTM), a Price-to-Book (P/B) ratio of 0.62x (TTM), at a market cap of $197.40M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 0.00%
Debt To Equity: 0.16x
P/S TTM: 98.70x
P/B TTM: 0.62x
Market Cap: $197.40M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is ORAMED PHARMACEUTICALS INC. in?

ORAMED PHARMACEUTICALS INC. (ORMP) operates in the Pharmaceutical Preparations industry.

What is ORMP's market cap?

ORAMED PHARMACEUTICALS INC. (ORMP) has a market capitalization of $197.40M as of 2026-06-30.

What is ORMP's P/E ratio?

ORAMED PHARMACEUTICALS INC. (ORMP)'s trailing twelve month P/E ratio is 3.08x as of 2026-06-30.

What exchange does ORMP trade on?

ORAMED PHARMACEUTICALS INC. (ORMP) trades on the Nasdaq.

Where is ORAMED PHARMACEUTICALS INC. incorporated?

ORAMED PHARMACEUTICALS INC. is incorporated in DE.